AAP IMPLANTATE AG |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.66 EUR | -9.59% |
|
-5.71% | -10.20% |
| 2021 | Aap Implantate AG Announces Sales Results for the Second Quarter and Half Year Ended 30 June 2021 | CI |
| 2021 | Aap Implantate Ag Reports Earnings Results for the Full Year Ended December 31, 2020 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -10.20% | 14.13M | - | ||
| -4.82% | 182B | C+ | ||
| +0.72% | 110B | C | ||
| -3.79% | 67.92B | A | ||
| +3.83% | 50.96B | B- | ||
| +9.24% | 44.7B | B- | ||
| +2.70% | 40.66B | B+ | ||
| +15.42% | 27.6B | B | ||
| +3.59% | 26.63B | A- | ||
| -0.01% | 24.98B | B |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AAQ1 Stock
- AAQ Stock
- Ratings aap Implantate AG